Timber Pharmaceuticals Inc is a company that upholds strong values and a clear corporate philosophy. It strives to prioritize the well-being of patients and the development of innovative healthcare solutions. With a commitment to improving lives, Timber Pharmaceuticals Inc focuses on delivering high-quality products and services. The company believes in investing in research and development to address unmet medical needs and enhance patient care. By valuing integrity, dedication, and collaboration, Timber Pharmaceuticals Inc aims to make a meaningful impact on the healthcare industry.

Timber Pharmaceuticals Inc is primarily present in the United States of America.

Timber Pharmaceuticals Inc has achieved several significant milestones. Recently, the company successfully completed a Phase 2b clinical trial for its lead product candidate, TMB-001, for the treatment of moderate to severe atopic dermatitis. These positive results demonstrated the potential efficacy and safety of TMB-001. Additionally, Timber Pharmaceuticals Inc has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for TMB-001, which recognizes the urgent need for innovative treatment options in the dermatology field. The company's dedication to advancing novel therapies has positioned Timber Pharmaceuticals Inc as a key player in the pharmaceutical industry.

Timber Pharmaceuticals Inc, a leading pharmaceutical company, has a rich history and a strong background in the healthcare industry. Founded in [insert year], the company has been dedicated to developing innovative and effective therapies for various medical conditions. Timber Pharmaceuticals Inc has established itself as a reliable player in the market, continually striving to improve patient care and outcomes. Throughout the years, the company has garnered recognition for its commitment to research and development, forging strategic partnerships, and delivering breakthrough treatments. With a focus on delivering value to its shareholders and improving global healthcare, Timber Pharmaceuticals Inc remains a trusted name in the pharmaceutical sector.

The main competitors of Timber Pharmaceuticals Inc in the market include companies such as Dermira Inc, Novartis International AG, and Johnson & Johnson. These companies operate in the pharmaceutical industry and offer products and services similar to Timber Pharmaceuticals Inc. However, Timber Pharmaceuticals Inc distinguishes itself through its unique product offerings and innovative approaches in addressing various dermatological conditions.

Timber Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Timber Pharmaceuticals Inc. focuses on developing and commercializing dermatology products. The company aims to address unmet medical needs in various dermatological conditions, including rare and orphan diseases. Timber Pharmaceuticals utilizes its expertise in clinical development, regulatory affairs, and product commercialization to bring innovative therapies to market. The company collaborates with key stakeholders, such as patients, physicians, and healthcare providers, to enhance patient care and provide effective treatment options. With its commitment to dermatology, Timber Pharmaceuticals Inc. strives to improve the quality of life for individuals suffering from dermatological disorders.

Timber Pharmaceuticals hissesinin F/K oranı -0,00.

Timber Pharmaceuticals KUV 0 dir.

Timber Pharmaceuticals için AlleAktien Kalite Skoru 4/10'dur.

Timber Pharmaceuticals için şu an ciro hesaplanamıyor.

beklenen Timber Pharmaceuticals karı -620,33 Milyon. USD olarak gerçekleşmiştir.

Timber Pharmaceuticals Inc. is a company based in New York City that is engaged in the development of medications and therapy options. The company aims to provide innovative solutions for a variety of diseases that currently have unsatisfactory treatment options. Timber Pharmaceuticals has developed a wide portfolio of products and pipelines focusing on different medical areas, including dermatology, oncology, and ophthalmology. The company's main focus is dermatology and it has developed some unique developments in this field. One example is Tamixofen, a topical medication developed by Timber Pharmaceuticals to alleviate the effects of eczema on the skin. The company also offers therapies for rare diseases, such as TMB-001 for the treatment of Xeroderma Pigmentosum. Timber Pharmaceuticals collaborates closely with leading medical experts and research institutions to continuously improve and develop its products and pipelines. In addition to its wide range of products, the company employs a strong marketing strategy, including collaborations with well-known companies in the healthcare industry. Overall, Timber Pharmaceuticals' business model is defined by innovation and a focus on providing groundbreaking innovations in the medical and pharmaceutical industries.

Timber Pharmaceuticals, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Timber Pharmaceuticals için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Timber Pharmaceuticals şirketinin ISIN kodu US8870801094’dir.

Timber Pharmaceuticals 'nin WKN'si A2P4ZX 'dir.

Timber Pharmaceuticals için Ticker TMBR’dir.

Son 12 ay içerisinde Timber Pharmaceuticals, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Timber Pharmaceuticals, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Timber Pharmaceuticals şirketinin mevcut temettü verimi .

Timber Pharmaceuticals dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Timber Pharmaceuticals, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Timber Pharmaceuticals, 'Sağlık' sektörüne atanmıştır.

Son Timber Pharmaceuticals tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 21.09.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 21.09.2024 olarak gerçekleşti.

2023 yılında Timber Pharmaceuticals tarafından 0 USD olarak temettüler dağıtıldı.

Timber Pharmaceuticals hisselerinin temettüleri USD olarak dağıtılır.